文献速递胸部肿瘤

遗传性ATM罕见有害变异增加肺腺癌风险

Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.
PubMed 文献 · J Thorac Oncol · 2020-08-28

该病例对照研究对1083例肺腺癌患者和7650例对照的胚系全外显子组测序数据进行分析,发现ATM罕见有害变异负荷在患者中显著高于对照(合并队列OR=4.6,p=1.7e-04,95%CI 2.2-9.5),并在MSK-IMPACT独立队列中验证。ATM是中等外显率肺腺癌风险基因,携带者可从加强监测中获益。

要点

  • ATM罕见有害变异携带者肺腺癌风险显著升高(合并OR=4.6)。
  • ATM相关癌症综合征谱可能包括肺腺癌。
  • 建议携带者加强CT监测、早期检测和化学预防。

核心结论

  • ATM是中等外显率肺腺癌风险基因,肺腺癌可能属于ATM相关癌症综合征谱。
  • 携带ATM罕见有害变异的个体肺腺癌风险升高,可从加强监测、早期检测和化学预防中获益。

研究设计与样本

  • 病例对照关联研究,对1083例肺腺癌患者和7650例对照的胚系全外显子组测序数据进行基因水平罕见有害变异负荷分析,分为发现队列和验证队列。
  • 其中97例患者进行全外显子组测序,其余数据来自多个公共数据库。
  • 使用ACMG指南和ClinVar注释所有罕见变异的致病性,采用惩罚逻辑回归分析基因水平罕见有害变异负荷,所有统计检验为双侧。

主要发现

  • 合并队列中ATM罕见有害变异负荷在肺腺癌患者中显著高于对照(OR=4.6,p=1.7e-04,95%CI 2.2-9.5),见于1.21%的病例和0.24%的对照。
  • 在MSK-IMPACT研究的1594例患者独立临床队列中,胚系ATM罕见有害变异亦富集(0.63%)。
  • Ashkenazi犹太人创始ATM变异rs56009889在Ashkenazi犹太病例中较对照显著更常见(合并AJ队列OR=2.7,p=6.9e-03,95%CI 1.3-5.3)。

临床怎么用

  • 对携带ATM罕见有害变异的个体,可考虑加强肺腺癌监测(特别是CT扫描)、早期检测和化学预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lung cancer is the leading cause of cancer deaths in the world, and lung adenocarcinoma (LUAD) is its most prevalent subtype. Symptoms are often found in advanced disease in which treatment options are limited. Identifying genetic risk factors will enable better identification of high-risk individuals. METHODS: To identify LUAD risk genes, we performed a case-control association study for gene-level burden of rare, deleterious variants (RDVs) in germline whole-exome sequencing data of 1083 patients with LUAD and 7650 controls, split into discovery and validation cohorts. Of these, we performed whole-exome sequencing on 97 patients and acquired the rest from multiple public databases. We annotated all rare variants for pathogenicity conservatively, using the guidelines of the American College of Medical Genetics and Genomics and ClinVar curation, and investigated gene-level RDV burden using penalized logistic regression. All statistical tests were two-sided. RESULTS: We discovered and replicated the finding that the burden of germline ATM RDVs was significantly higher in patients with LUAD versus controls (combined cohort OR = 4.6; p = 1.7e-04; 95% confidence interval = 2.2-9.5; 1.21% of cases; 0.24% of controls). Germline ATM RDVs were also enriched in an independent clinical cohort of 1594 patients from the MSK-IMPACT study (0.63%). In addition, we observed that an Ashkenazi Jewish (AJ) founder ATM variant, rs56009889, was statistically significantly more frequent in AJ cases versus AJ controls in our cohort (combined AJ cohort OR = 2.7, p = 6.9e-03, 95% confidence interval = 1.3-5.3). CONCLUSIONS: Our results indicate that ATM is a moderate-penetrance LUAD risk gene and that LUAD may be a part of the ATM-related cancer syndrome spectrum. Individuals with ATM RDVs are at an elevated LUAD risk and can benefit from increased surveillance (particularly computed tomography scanning), early detection, and chemoprevention programs, improving prognosis.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Esai Selvan M, Zauderer MG, Rudin CM, et al. Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. J Thorac Oncol. 2020. PMID: 32866655. doi:10.1016/j.jtho.2020.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。